Pharmacologic control of CAR T therapies may provide an improved T cell product and better outcomes for patients with cancer
DeCART Therapeutics is a biotechnology company founded by a team of scientific and business leaders including Carl H. June, M.D., Joseph A. Fraietta, Ph.D., Xianxin Hua, M.D., Ph.D., and Dana M. Hammill, M.S., M.B.A., from the University of Pennsylvania, and Arthur T. Sands, M.D., Ph.D. and Pierre Beaurang, Ph.D. from Nurix Therapeutics.
Carl H. June, M.D., Founder
Chairman Scientific Advisory Board
Carl June, M.D. is a founder of DeCART and serves as the Chairman of the Company’s Scientific Advisory Board. He is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine and currently serves as Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. He is a graduate of the Naval Academy in Annapolis, and Baylor College of Medicine in Houston, 1979. He completed graduate training in Immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland from 1978-1979, and postdoctoral training in transplantation biology with E. Donnell Thomas and John Hansen at the Fred Hutchinson Cancer Research Center in Seattle from 1983-1986. He is board certified in Internal Medicine and Medical Oncology. Dr. June pioneered the CART19 therapy, which has revolutionized cancer treatments across the world. Dr. June has published more than 350 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine (2012) and the American Academy of Arts and Sciences (2014), TIME 100 most influential people in the world (2018), the Albany Prize (2018), and the Philadelphia Award (2013).
Arthur T. Sands, M.D. Ph.D., Founder
Executive Chairman of the Board of Directors
Arthur T. Sands, M.D., Ph.D., is a founder of DeCART and currently serves as the Executive Chairman of the Board of Directors. Since September 2014, Dr. Sands has served as the Chief Executive Officer of Nurix Therapeutics and a member of the company’s Board of Directors. Prior to joining Nurix, Dr. Sands was the co-founder and served as President, Chief Executive Officer and as a member of the Board of Directors of Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on target validation and pharmaceutical development, from 1995 to July 2014. Before founding Lexicon Pharmaceuticals, Dr. Sands was an American Cancer Society postdoctoral fellow in the Department of Human and Molecular Genetics at Baylor College of Medicine. Dr. Sands holds a B.A. in Economics and Political Science from Yale University and an M.D. and a Ph.D. in Cell Biology from Baylor College of Medicine.
Joseph A. Fraietta Ph.D., Founder
Member Scientific Advisory Board
Dr. Fraietta is a founder of DeCART and serves on the Company’s Scientific Advisory Board. He currently directs the Solid Tumor Immunotherapy Laboratory in the Center for Cellular Immunotherapies at the University of Pennsylvania’s Perelman School of Medicine. As a postdoctoral fellow under the tutelage of Dr. June, Dr. Fraietta developed novel approaches for the treatment of cancer through genetic modification of T lymphocytes that contributed to the initiation of multiple clinical trials and U.S. FDA approval of the first CAR T cell therapy. His high-impact findings have been published in Nature, Nature Medicine, Nature Immunology and Science Translational Medicine. Dr. Fraietta is the recipient of numerous awards, including a Microbiology and Immunology Distinguished Alumni Award and a 2019 National Clinical Research Award from the Clinical Research Forum. He holds a B.S. in Bioscience and Biotechnology and a Ph.D. in Microbiology and Immunology from Drexel University.
Xianxin Hua M.D. Ph.D., Founder
Member Scientific Advisory Board
Dr. Hua is a founder of DeCART and currently serves on the Company’s Scientific Advisory Board. He is a professor of Cancer Biology at the University of Pennsylvania’s Perelman School of Medicine and an investigator at the Abramson Family Cancer Research Institute and the Institute of Translational Medicine and Therapeutics. Dr. Hua has extensive experience in discovering novel therapeutic targets and generating effective antibodies and CAR Ts for the treatment of liquid and solid tumors. He is a recipient of the Harrington Discovery Institute Innovative scholar award. Dr. Hua holds an M.D. from Hubei Medical College and a Ph.D. in Cell Regulation from the Department of Molecular Genetics at The University of Texas Southwestern Medical Center at Dallas.
Dana M. Hammill M.S. M.B.A., Founder
Chief Operating Officer
Ms. Hammill is a founder of DeCART and serves as the Chief Operating Officer. Prior to founding DeCART, she served as the Director of Strategy and Business Development for the Center for Cellular Immunotherapies at the University of Pennsylvania’s Perelman School of Medicine. Notably in this role, Ms. Hammill managed the Penn-Novartis alliance, including the finance committee, for the FDA approval of the first CAR T cell therapy in the United States. She brings over 20 years of experience in translational and clinical research to DeCART, specifically in cell and gene therapies, and extensive experience with start-ups, incubations and fund raising. Ms. Hammill earned a B.S. in Biotechnology from Rutgers University, followed by an M.S. in Genetic Engineering from the University of Pennsylvania and an M.B.A. from Saint Joseph’s University.
Pierre Beaurang Ph.D., Founder
Dr. Beaurang is a founder of DeCART and currently serves as Chief Business Officer at Nurix Therapeutics. Prior to joining Nurix, Dr. Beaurang was part of the founding team of Five Prime Therapeutics where he contributed to the conceptualization, creation and implementation of the company plan. Dr. Beaurang held roles of increasing responsibility and negotiated several major collaborations with global pharmaceutical firms, including GlaxoSmithKline, UCB and Bristol Myers Squibb, helping secure an aggregate $270 million in near term revenues and more than $2.4 billion in potential milestone payments. Dr. Beaurang holds a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley and conducted postdoctoral research at the University of California, San Francisco. He holds a B.A. in Biology and an M.A. in Biotechnology from Boston University.